FineMark National Bank & Trust’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $567K | Hold |
4,650
| – | – | 0.02% | 296 |
|
|
2025
Q3 | $466K | Sell |
4,650
-75
| -2% | -$6.75K | 0.02% | 318 |
|
|
2025
Q2 | $392K | Sell |
4,725
-76
| -2% | -$6.06K | 0.01% | 337 |
|
|
2025
Q1 | $389K | Sell |
4,801
-110
| -2% | -$9.83K | 0.01% | 324 |
|
|
2024
Q4 | $442K | Sell |
4,911
-200
| -4% | -$19.4K | 0.02% | 298 |
|
|
2024
Q3 | $505K | Sell |
5,111
-150
| -3% | -$14.7K | 0.02% | 285 |
|
|
2024
Q2 | $488K | Hold |
5,261
| – | – | 0.02% | 278 |
|
|
2024
Q1 | $499K | Buy |
5,261
+385
| +8% | +$35.7K | 0.02% | 282 |
|
|
2023
Q4 | $435K | Hold |
4,876
| – | – | 0.02% | 290 |
|
|
2023
Q3 | $356K | Sell |
4,876
-81
| -2% | -$6.47K | 0.02% | 307 |
|
|
2023
Q2 | $412K | Buy |
+4,957
| New | +$415K | 0.02% | 300 |
|
|
2023
Q1 | – | Sell |
-2,714
| Closed | -$225K | – | 439 |
|
|
2022
Q4 | $225K | Buy |
+2,714
| New | +$220K | 0.01% | 362 |
|
|
2022
Q2 | – | Sell |
-2,644
| Closed | -$238K | – | 456 |
|
|
2022
Q1 | $238K | Buy |
2,644
+28
| +1% | +$2.59K | 0.01% | 400 |
|
|
2021
Q4 | $293K | Hold |
2,616
| – | – | 0.01% | 387 |
|
|
2021
Q3 | $329K | Buy |
2,616
+76
| +3% | +$9.79K | 0.01% | 345 |
|
|
2021
Q2 | $344K | Sell |
2,540
-43
| -2% | -$5.65K | 0.01% | 345 |
|
|
2021
Q1 | $350K | Buy |
2,583
+258
| +11% | +$38.6K | 0.01% | 329 |
|
|
2020
Q4 | $327K | Buy |
+2,325
| New | +$298K | 0.01% | 326 |
|
|
2018
Q3 | – | Sell |
-5,160
| Closed | -$491K | – | 411 |
|
|
2018
Q2 | $491K | Hold |
5,160
| – | – | 0.03% | 250 |
|
|
2018
Q1 | $453K | Hold |
5,160
| – | – | 0.03% | 261 |
|
|
2017
Q4 | $438K | Hold |
5,160
| – | – | 0.03% | 249 |
|
|
2017
Q3 | $447K | Sell |
5,160
-50
| -1% | -$4.01K | 0.03% | 248 |
|
|
2017
Q2 | $402K | Buy |
5,210
+360
| +7% | +$25.5K | 0.03% | 251 |
|
|
2017
Q1 | $336K | Buy |
4,850
+50
| +1% | +$3.36K | 0.02% | 274 |
|
|
2016
Q4 | $284K | Hold |
4,800
| – | – | 0.02% | 289 |
|
|
2016
Q3 | $318K | Hold |
4,800
| – | – | 0.03% | 266 |
|
|
2016
Q2 | $260K | Hold |
4,800
| – | – | 0.03% | 280 |
|
|
2016
Q1 | $248K | Hold |
4,800
| – | – | 0.03% | 282 |
|
|
2015
Q4 | $337K | Hold |
4,800
| – | – | 0.04% | 247 |
|
|
2015
Q3 | $299K | Sell |
4,800
-3,090
| -39% | -$244K | 0.04% | 271 |
|
|
2015
Q2 | $663K | Buy |
7,890
+600
| +8% | +$46.7K | 0.09% | 184 |
|
|
2015
Q1 | $548K | Buy |
7,290
+2,400
| +49% | +$168K | 0.07% | 208 |
|
|
2014
Q4 | $304K | Hold |
4,890
| – | – | 0.04% | 278 |
|
|
2014
Q3 | $254K | Hold |
4,890
| – | – | 0.04% | 295 |
|
|
2014
Q2 | $251K | Hold |
4,890
| – | – | 0.04% | 295 |
|
|
2014
Q1 | $232K | Hold |
4,890
| – | – | 0.04% | 294 |
|
|
2013
Q4 | $212K | Buy |
4,890
+240
| +5% | +$9.94K | 0.04% | 298 |
|
|
2013
Q3 | $200K | Buy |
+4,650
| New | +$188K | 0.05% | 299 |
|
Other funds holding XBI
ACA
FineMark National Bank & Trust's XBI Position: Q4 2025 in Review
FineMark National Bank & Trust held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q4 2025 at 4,650 shares worth $567K. The position accounts for 0.02% of the portfolio, ranked #296.
FineMark National Bank & Trust first reported a position in XBI in Q3 2013 and has held it in 38 quarters since. The position peaked at $663K in Q2 2015. 813 funds tracked by Wall St. Rank hold XBI as of Q4 2025.
- FineMark National Bank & Trust held 4,650 shares of State Street SPDR S&P Biotech ETF worth $567K as of Q4 2025.
- FineMark National Bank & Trust left its State Street SPDR S&P Biotech ETF share count unchanged in Q4 2025.
- State Street SPDR S&P Biotech ETF made up 0.02% of FineMark National Bank & Trust's portfolio in Q4 2025, its #296 holding.
- FineMark National Bank & Trust first reported a position in State Street SPDR S&P Biotech ETF in Q3 2013 and has held it in 38 quarters since.
- FineMark National Bank & Trust's State Street SPDR S&P Biotech ETF position peaked at $663K in Q2 2015.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.
Based on FineMark National Bank & Trust's 13F filing for Q4 2025, filed 12 Feb 2026.